Black Hawk Acquisition Corporation Announces Redemption Results in Connection With Its Business Combination With Vesicor Therapeutics Inc.
Black Hawk Acquisition Shareholders Approve Its Proposed Business Combination With Vesicor Therapeutics
Black Hawk Acquisition Corp and Vesicor Therapeutics Enter Forward Purchase Agreement with Meteora for Up to 1.35M Shares; Company To Domesticate As A Delaware Corporation And Change Name To Vesicor Therapeutics Holdings; Co To Pay Meteora Final Redemption Price Less $0.75 Per Backstop Investor Share; Vesicor Therapeutics Holdings May Sell Up To $200M Of Common Stock To Meteora Over 36 Months
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
Black Hawk Acquisition Corporation Amends Its Definitive Proxy Statement
Vesicor Therapeutics, Inc. and Black Hawk Acquisition Corporation Enter into a Business Combination Agreement to Create a Biotechnology Company Advancing p53-based Cancer Therapeutics Delivered Via Microvesicles
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
